news
-
JFMN 2025
- February 14, 2025
11th Annual Congress of JFMN (Journées Francophones de Médecine Nucléaire)
March 20-22, 2025
Montrouge, France
Booth #6a -
ALFIM Congress 2025
- February 13, 2025
10th Latin American Congress of Medical Physics (ALFIM)
March 9-12, 2025
La Antigua, Guatemala
Patient QA showcase on Elekta booth -
Happy New Year 2025
- December 26, 2024
-
Dosisoft Planet®: Enhancing and Expanding Dosimetry for More Personalised Patient Therapy
- December 15, 2024
End-to-end, versatile and vendor-neutral, PLANET® is recognized as the most comprehensive software solution for theranostics and patient-specific dosimetry applied to nuclear medicine.
-
[Article] Dosimetric Evaluation of 177Lu Peptide Receptor Radionuclide Therapy Using GATE and Planet Dose
- December 6, 2024
Ioanna Stamouli, Thomas Nanos, Konstantinos Chatzipapas, Panagiotis Papadimitroulas, Lydia-Aggeliki Zoglopitou, et al.
Appl. Sci. 2023, 13, 9836. | https://doi.org/10.3390/app13179836 -
ALATRO Congress 2024
- November 4, 2024
9th Asociación Ibero-Latinoamericana de Terapia Radiante Oncológica (ALATRO) Meeting
November 6-9, 2024
Río de Janeiro, Brasil
Patient QA showcase on Elekta booth -
DOSIsoft Contributing Partner of the European Thera4Care project – Theranostics Ecosystem For Personalized Care
- October 11, 2024
DOSIsoft is proud to be part of the EU-funded Thera4care Project – a public-private initiative aiming to revolutionize precision oncology and establish Europe as a global leader in Theranostics. Contributing with its own R&D and granted 1,6 million€ of EU funding, DOSIsoft will focus its efforts on the further development of dosimetry software, sharing the vision that personalized dosimetry becomes a standard clinical practice.
-
DOSIsoft & AP-HP: A Scientific partnership on « QUANTHYR » – 1st Software dedicated to Personalized Diagnosis and Dosimetry Treatment of Hyperthyroidism with 131Iodine
- October 1, 2024
RESEARCH & INNOVATION IN NUCLEAR MEDICINE: To improve cancer patient safety and treatment quality, DOSIsoft announces that it has signed a development and commercialization agreement (license) with the Assistance Publique – Hôpitaux de Paris (AP-HP) for a Radioiodine theranostic solution applied to benign thyroid diseases named “QUANTHYR”.
-
EANM Annual Congress 2024
- September 6, 2024
The 37th Annual Congress of the European Association of Nuclear Medicine
October 19-23, 2024
Hamburg, Germany
Booth #S4 -
ASTRO Annual Meeting 2024
- August 14, 2024
The 66th American Society for Radiation & Oncology (ASTRO) Annual Meeting
September 29-October 2, 2024
Washington, DC, USA
Patient QA showcase on Elekta booth #2227